PEOPLE - Neoprobe (US) makes appointment:
This article was originally published in Clinica
Oncology and cardiovascular surgical and diagnostic developer Neoprobe (Dublin, Ohio) has appointed Carl Aschinger to its board of directors. His term runs until 2005, when he will stand for election for another term ending in 2008. Mr Aschinger has been a member of the board of directors of several Columbus, Ohio-based companies.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.